齐拉西酮针剂治疗急性精神分裂症激越患者的临床研究  

Clinical study of ziprasidone injection in the treatment of agitation in acute schizophrenia

作　　者：朱敏捷[1] 严峰 林翔 白艳乐 李霞[1] ZHU Minjie;YAN Feng;LIN Xiang;BAI Yanle;LI Xia(Department of Geriatric Psychiatry,Mental Health Center,School of Medicine,Shanghai Jiaotong University,Shanghai 200030,China)

机构地区：[1]上海交通大学医学院附属精神卫生中心,上海200030

出　　处：《徐州医科大学学报》2022年第1期41-44,共4页Journal of Xuzhou Medical University

摘　　要：目的研究齐拉西酮针剂治疗急性精神分裂症激越患者的临床效果。方法选择上海交通大学医学院附属精神卫生中心2017年1月—2019年1月治疗的118例精神分裂症激越患者作为研究对象,按照随机分组原则分为观察组和对照组,每组59例。观察组患者采取齐拉西酮治疗,对照组采取氟哌啶醇治疗,均治疗3 d。观察2组患者的PANSS评分、PANSS-EC评分、BARS评分之间的差异,分析2组患者的不良反应发生情况。结果观察组患者的治疗总有效率(89.83%)显著高于对照组(74.58%),差异有统计学意义(χ^(2)=4.692,P=0.030)。治疗30 min以及2 h后,2组患者的PANSS-EC以及BARS评分均显著降低,且观察组患者的PANSSEC(t=3.401,9.812,P<0.05)以及BARS评分(t=2.120,2.519,P<0.05)显著低于对照组;2组患者发生静坐不能(χ^(2)=0.165,P=0.684)、体重增加(χ^(2)=0.521,P=0.470)、口干便秘(χ^(2)=0.179,P=0.672)以及心动过速(χ^(2)=0.202,P=0.657)等不良反应之间的差异无统计学意义。结论齐拉西酮针剂治疗急性精神分裂症激越患者的PANSS-EC以及BARS评分均显著降低,治疗效果显著,建议推广。Objective To investigate the clinical effect of ziprasidone injection in the treatment of schizophrenic agitation patients.Methods A total of 118 schizophrenic agitation patients who were treated in Mental Health Center,School of Medicine,Shanghai Jiaotong University from January 2017 to January 2019 were enrolled.They were randomly divided into two groups(n=59):an observation group and a control group.The observation group was treated with ziprasidone,while the control group was treated with haloperidol for three days.Both groups were compared for PANSS score,PANSS-EC score and BARS score.Their incidences of adverse reactions were observed.Results The total effective rate of the observation group(89.83%)was significantly higher than that of the control group(74.58%)(χ^(2)=4.692,P=0.030).After 30 min and 2 h of treatment,the PANSS-EC and BARS scores of the two groups significantly decreased,and the PANSS-EC(t=3.401,9.812,P<0.05)and BAR scores(t=2.120,2.519,P<0.05)of the observation group were significantly lower than those of the control group.There was no significant difference between the two groups in sedentary disability(χ^(2)=0.165,P=0.684),weight gain(χ^(2)=0.521,P=0.470),dry mouth constipation(χ^(2)=0.179,P=0.672)and tachycardia(χ^(2)=0.202,P=0.657).Conclusions Ziprasidone injection can effectively treat schizophrenic agitation patients,with decreased PANSS score,PANSS-EC and BARS scores.

关 键 词：齐拉西酮 激越 PANSS评分 BARS评分 

分 类 号：R749.3[医药卫生—神经病学与精神病学]